Supportive and palliative care


Validation of a new risk-assessment model for prediction of Venous Thromboembolism in cancer outpatients: the ONKOTEV score

C.A. Cella, et al.


ONKOTEV score ≥ 2 identified a category of high-risk group of cancer outpatients and significantly improved the VTE predictability of pre-existing RAMs. Therefore, ONKOTEV score has been validated as a new easy-to-use RAM for risk stratification and decision making about primary prophylaxis in cancer outpatients, with promising implications in clinical practice. The study was awarded within the EORTC Young Investigator program (2015-2018).



Differences in hematologists’ and palliative care physicians’ recommended indications and opinions on transfusion therapy for patients with hematological malignancy post-anticancer therapy

Y. Hattori, et al.


There are differences in the opinions of HOs and PCs regarding the indication for undergoing transfusion therapy for patients with end-stage hematological malignancies. In the future, it is expected that the referral rate of palliative care for patients with end-stage hematological malignancies will increase through mutual understanding and consensus on transfusion therapy.



Impact of Antibiotic (ATB) Exposure Prior to Immune Checkpoint Inhibitor (ICI) Treatment on Overall Survival (OS): A Population Based Study

L. Eng, et al.


Exposure to ATBs and specifically fluroquinolones prior to ICI therapy is associated with worse OS. Interventions aimed at altering the gut microbiome may be required to help improve outcomes for patients on ICIs with prior ATB exposure.



Efficacy and Safety of Tanezumab in Subjects with Cancer Pain Predominantly Due to Bone Metastasis Receiving Background Opioid Therapy

M. Fallon, et al.


Tanezumab 20 mg improved metastatic cancer-related bone pain compared with placebo and the AE profile was generally consistent with previous studies of tanezumab.



Placebo-controlled, double-blinded phase study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial

K. Shimomura, et al.


DEX administration on days 2 to 4 can be spared when combined with NK1-RA, PALO, and OLZ 5 mg in CDDP-containing HEC.



Olanzapine, an Alternative to Dexamethasone for Preventing Nausea and Vomiting Induced by Cisplatin-Based Doublet Highly Emetogenic Chemotherapy: A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase 3 Clinical Trial

Z. Liu, et al.


Olanzapine (5mg) could be a non-inferiority alternative of dexamethasone in the triplet combination anti-emetic therapy and has less side effects than dexamethasone.